Literature DB >> 19258264

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

George R Thompson, Michael G Rinaldi, Gennethel Pennick, Sheryl A Dorsey, Thomas F Patterson, James S Lewis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19258264      PMCID： PMC2681542          DOI： 10.1128/AAC.00240-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.

Authors:  Paul O Gubbins; Gopal Krishna; Angela Sansone-Parsons; Scott R Penzak; Li Dong; Monika Martinho; Elias J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

Authors:  A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

4.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

Review 5.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

7.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.

Authors:  Gopal Krishna; Monika Martinho; Pranatharthi Chandrasekar; Andrew J Ullmann; Hernando Patino
Journal:  Pharmacotherapy       Date:  2007-12       Impact factor: 4.705
  8 in total
  31 in total

1.  Intracellular concentrations of posaconazole in different compartments of peripheral blood.

Authors:  Fedja Farowski; Oliver A Cornely; Jörg J Vehreschild; Pia Hartmann; Tim Bauer; Angela Steinbach; Maria J G T Rüping; Carsten Müller
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.

Authors:  Bertrand Rochat; Andres Pascual; Benoît Pesse; Frédéric Lamoth; Dominique Sanglard; Laurent A Decosterd; Jacques Bille; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

3.  Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

Authors:  J J Vehreschild; C Müller; F Farowski; M J G T Vehreschild; O A Cornely; U Fuhr; K-A Kreuzer; M Hallek; V Kohl
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

4.  Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.

Authors:  Piergiorgio Cojutti; Anna Candoni; Erica Simeone; Loretta Franceschi; Renato Fanin; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

5.  What is the role of therapeutic drug monitoring in antifungal therapy?

Authors:  Jeannina A Smith
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

Review 6.  [Innovative antifungals for treatment of invasive fungal infections].

Authors:  A Glöckner
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

7.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

8.  Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake.

Authors:  C Eiden; J C Meniane; H Peyrière; S Eymard-Duvernay; G Le Falher; P Ceballos; N Fegueux; M Cociglio; J Reynes; D Hillaire-Buys
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-26       Impact factor: 3.267

9.  Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.

Authors:  Luciana Annino; Anna Chierichini; Barbara Anaclerico; Erica Finolezzi; Marianna Norata; Stefania Cortese; Maria Iris Cassetta; Stefania Fallani; Andrea Novelli; Corrado Girmenia
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

Review 10.  Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

Authors:  Emily Zoller; Connie Valente; Kyle Baker; Michael E Klepser
Journal:  Drug Des Devel Ther       Date:  2010-11-04       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.